Page last updated: 2024-12-06
isonixin
Description
isonixin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 68767 |
| CHEMBL ID | 2105035 |
| CHEBI ID | 134986 |
| SCHEMBL ID | 24519 |
| MeSH ID | M0064467 |
Synonyms (39)
| Synonym |
|---|
| nixyn |
| isonixin [inn] |
| isonixinum [inn-latin] |
| 3-pyridinecarboxamide, 1,2-dihydro-2-oxo-n-(2,6-xylyl)- |
| einecs 260-521-6 |
| isonixine |
| isonixin |
| 2,6-xylidide of 2-pyridone-3-carboxylic acid |
| 1,2-dihydroxy-2-oxo-n-(2,6-xylyl)-3-pyridinecarboxamide |
| isonixine [inn-french] |
| nixyn hermes |
| n-(2,6-dimethylphenyl)-1,2-dihydro-2-oxo-3-pyridinecarboxamide |
| isonixina [inn-spanish] |
| 2-hydroxy-2',6'-nicotinoxylidide |
| 2,6-xylidid der 2-pyridon-3-carboxylsaure [german] |
| 3-pyridinecarboxamide, n-(2,6-dimethylphenyl)-1,2-dihydro-2-oxo- |
| CHEBI:134986 |
| n-(2,6-dimethylphenyl)-2-oxo-1h-pyridine-3-carboxamide |
| 57021-61-1 |
| D08089 |
| nixyn hermes (tn) |
| isonixin (inn) |
| byx6e7m5qe , |
| isonixinum |
| 2,6-xylidid der 2-pyridon-3-carboxylsaure |
| isonixina |
| unii-byx6e7m5qe |
| CHEMBL2105035 |
| isonixin [mart.] |
| isonixin [mi] |
| isonixin [who-dd] |
| SCHEMBL24519 |
| AKOS027597705 |
| AKOS027475368 |
| Q3803297 |
| n-(2,6-dimethylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide |
| DTXSID80877494 |
| CS-0026275 |
| HY-105579 |
Drug Classes (1)
| Class | Description |
|---|
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 3 (27.27%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (9.09%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (63.64%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |